NMAD — NOMAD Power Solutions Share News
0.000.00%
Last trade - 00:00Lixte more than doubles on promising cancer drug data; tops premarket gainers
Brief: LIXTE Biotechnology Reports Preclinical Results of its Collaboration with Netherlands Cancer Institute
Brief: Lixte Biotechnology Announces Filing Of First Patent Application Resulting From Collaboration With The Netherlands Cancer Institute
U.S. STOCKS ON THE MOVE-Salesforce, Mainz Biomed
U.S. STOCKS ON THE MOVE-Accenture, Lennar, Novavax, Calliditas Therapeutics
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:24 PM
Brief: Lixte Biotechnology Holdings, Inc. Announces That Enrollment Has Resumed In National Cancer Institute’S Trial To Determine Ability Of Lixte Compound Lb-100 To Enter Recurrent, Malignant Brain Tumors
Brief: Lixte Biotechnology Holdings Inc Collaboration With Netherlands Cancer Institute And Oncode Institute To Identify Promising Drugs To Be Combined With LB-100
Brief: Lixte Biotechnology Holdings Inc Announces The Appointment Of Gil N Schwartzberg To Its Board Of Directors
Brief: Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
Brief: Lixte Biotechnology Files For Mixed Shelf Of Up To $20 Million
U.S. STOCKS ON THE MOVE-General Motors, Gilead Sciences, Aclaris, Facebook, ODP
Lixte: Rises on agreement with medical center for lung cancer drug trial
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM